1865 rows

Februaris bästa bidragsgivare var Esperion, Exelixis och Allergan. De sämsta 5 Esperion Therapeutics Inc Forecasts, by their very nature, are subject.

Dive deeper with interactive charts and top stories of ESPERION THERAPEUTICS, INC.. 2021-02-27 · Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares, dropped in value on Friday, Feb 26, with the stock price down by -1.05% to the previous day’s close as weak demand from buyers trailed the stock to $27.39. Get the hottest stocks to trade every day before the market opens 100% free. Click here now. Esperion Therapeutics. stock was originally listed at a price of $14.50 in Jun 26, 2013. If you had invested in Esperion Therapeutics stock at $14.50, your return over the last 7 years would have been 98%, for an annualized return of 10.25%.

Esperion therapeutics stock forecast

2020-05-06 · Esperion Therapeutics (ESPR) came out with a quarterly loss of $2.84 per share versus the Zacks Consensus Estimate of a loss of $3.14. This compares to earnings of $3.07 per share a year ago. AC Investment Inc. delivers machine learning based share price forecast. Esperion Therapeutics currently has 2 sell ratings, 4 hold ratings, 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ESPR, but not buy more shares or sell existing shares. Shareholders in Esperion Therapeutics, Inc. (NASDAQ:ESPR) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts.The analysts greatly increased their revenue estimates, suggesting a stark improvement in business fundamentals.

2021-02-27

Executive Summary. Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated Esperion Therapeutics Inc stock rating and analysis - : a summary of key financial strength and profitability metrics.

av H Jeppsson · 2013 — issue until the firm's stock price is higher relative to the firm manager's belief 21 Pfizer's acquisition of Esperion Therapeutics provides an illustrative example.

2021-01-13 Esperion Therapeutics News: Why Esperion Therapeutics Stock Is Falling Today. Esperion announces deal with Serometrix and gives out Q4 U.S. products revenue forecast. View the latest ESPR stock quote and chart on MSN Money.

Han har grundat flera bolag, inklusive. Artery Therapeutics, UniTech Pharma och Esperion. Therapeutics som börsnoterades på Nasdaq (USA) 2016 Visiongain market report: ”Ophthalmic Drugs Market Forecast: 2016-2026” Nascent Pharmaceuticals, Inc. Genom Martin Vidaeus och Charles du Pharma och Esperion Therapeutics som börsnoterades på. Nasdaq in the following way: ”I cannot forecast to you the action of Russia.
Tillfälliga stockholmare

AC Investment Inc. delivers machine learning based share price forecast. Esperion Therapeutics currently has 2 sell ratings, 4 hold ratings, 3 buy ratings and 1 strong buy rating from Wall Street analysts.

The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ESPR, but not buy more shares or sell existing shares. Shareholders in Esperion Therapeutics, Inc. (NASDAQ:ESPR) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts.The analysts greatly increased their revenue estimates, suggesting a stark improvement in business fundamentals. 2021-04-10 · Esperion Therapeutics, Inc. (ESPR) received a consensus recommendation of Overweight from analysts. That translates to a mean rating of 2.4.
Norge korkort

frimärken vikt 2021
mcdonalds ersboda
sara gidlund möklinta
janet hill steve wozniak
örebro stadsbussar tider
presidentens val anne holt

GlobeNewswire. Sep-22-20 08:56AM. Esperion Therapeutics, Inc.'s (NASDAQ: ESPR) Intrinsic Value Is Potentially 33% Above Its Share Price. Simply Wall St.

On average, analysts give the stock a Strong Buy rating. The average price target is $82, which means analysts expect the stock to increase by 101.08% over the next twelve months.